### PART B—GENERAL PROVISIONS RESPECTING NATIONAL RESEARCH INSTITUTES

### §284. Directors of national research institutes
#### (a) Appointment
* #### (1) In general
  * The Director of the National Cancer Institute shall be appointed by the President, and the Directors of the other national research institutes and national centers shall be appointed by the Secretary, acting through the Director of National Institutes of Health. Each Director of a national research institute or national center shall report directly to the Director of National Institutes of Health.

* #### (2) Appointment
  * #### (A) Term
    * A Director of a national research institute or national center who is appointed by the Secretary, acting through the Director of National Institutes of Health, shall be appointed for 5 years.

  * #### (B) Reappointment
    * At the end of the term of a Director of a national research institute or national center, the Director may be reappointed in accordance with standards applicable to the relevant appointment mechanism. There shall be no limit on the number of terms that a Director may serve.

  * #### (C) Vacancies
    * If the office of a Director of a national research institute or national center becomes vacant before the end of such Director's term, the Director appointed to fill the vacancy shall be appointed for a 5-year term starting on the date of such appointment.

  * #### (D) Current directors
    * Each Director of a national research institute or national center who is serving on December 13, 2016, shall be deemed to be appointed for a 5-year term under this subsection beginning on such date.

  * #### (E) Rule of construction
    * Nothing in this subsection shall be construed to limit the authority of the Secretary or the Director of National Institutes of Health to terminate the appointment of a director referred to in subparagraph (A) before the expiration of such director's 5-year term.

  * #### (F) Nature of appointment
    * Appointments and reappointments under this subsection shall be made on the basis of ability and experience as it relates to the mission of the National Institutes of Health and its components, including compliance with any legal requirement that the Secretary or Director of National Institutes of Health determines relevant.

* #### (3) Nonapplication of certain provision
  * The restrictions contained in section 202 of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 1993 (Public Law 102–394; 42 U.S.C. 238f note) related to consultants and individual scientists appointed for limited periods of time shall not apply to Directors appointed under this subsection.

#### (b) Duties and authority; grants, contracts, and cooperative agreements
* (1) In carrying out the purposes of section 241 of this title with respect to human diseases or disorders or other aspects of human health for which the national research institutes were established, the Secretary, acting through the Director of each national research institute—

  * (A) shall encourage and support research, investigations, experiments, demonstrations, and studies in the health sciences related to—

    * (i) the maintenance of health,

    * (ii) the detection, diagnosis, treatment, and prevention of human diseases and disorders,

    * (iii) the rehabilitation of individuals with human diseases, disorders, and disabilities, and

    * (iv) the expansion of knowledge of the processes underlying human diseases, disorders, and disabilities, the processes underlying the normal and pathological functioning of the body and its organ systems, and the processes underlying the interactions between the human organism and the environment;


  * (B) may, subject to the peer review prescribed under section 289a(b) of this title and any advisory council review under section 284a(a)(3)(A)(i) of this title, conduct the research, investigations, experiments, demonstrations, and studies referred to in subparagraph (A);

  * (C) shall, as appropriate, conduct and support research that has the potential to transform the scientific field, has inherently higher risk, and that seeks to address major current challenges;

  * (D) may conduct and support research training (i) for which fellowship support is not provided under section 288 of this title, and (ii) which is not residency training of physicians or other health professionals;

  * (E) may develop, implement, and support demonstrations and programs for the application of the results of the activities of the institute to clinical practice and disease prevention activities;

  * (F) may develop, conduct, and support public and professional education and information programs;

  * (G) may secure, develop and maintain, distribute, and support the development and maintenance of resources needed for research;

  * (H) may make available the facilities of the institute to appropriate entities and individuals engaged in research activities and cooperate with and assist Federal and State agencies charged with protecting the public health;

  * (I) may accept unconditional gifts made to the institute for its activities, and, in the case of gifts of a value in excess of $50,000, establish suitable memorials to the donor;

  * (J) may secure for the institute consultation services and advice of persons from the United States or abroad;

  * (K) may use, with their consent, the services, equipment, personnel, information, and facilities of other Federal, State, or local public agencies, with or without reimbursement therefor;

  * (L) may accept voluntary and uncompensated services; and

  * (M) may perform such other functions as the Secretary determines are needed to carry out effectively the purposes of the institute.


* The indemnification provisions of section 2354 of title 10 shall apply with respect to contracts entered into under this subsection and section 282(b) of this title.

* (2) Support for an activity or program under this subsection may be provided through grants, contracts, and cooperative agreements. The Secretary, acting through the Director of each national research institute—

  * (A) may enter into a contract for research, training, or demonstrations only if the contract has been recommended after technical and scientific peer review required by regulations under section 289a of this title;

  * (B) may make grants and cooperative agreements under paragraph (1) for research, training, or demonstrations, except that—

    * (i) if the direct cost of the grant or cooperative agreement to be made does not exceed $50,000, such grant or cooperative agreement may be made only if such grant or cooperative agreement has been recommended after technical and scientific peer review required by regulations under section 289a of this title, and

    * (ii) if the direct cost of the grant or cooperative agreement to be made exceeds $50,000, such grant or cooperative agreement may be made only if such grant or cooperative agreement has been recommended after technical and scientific peer review required by regulations under section 289a of this title and is recommended under section 284a(a)(3)(A)(ii) of this title by the advisory council for the national research institute involved; and


  * (C) shall, subject to section 300cc–40c(d)(2) of this title, receive from the President and the Office of Management and Budget directly all funds appropriated by the Congress for obligation and expenditure by the Institute.


* (3) Before an award is made by a national research institute or by a national center for a grant for a research program or project (commonly referred to as an "R-series grant"), other than an award constituting a noncompetitive renewal of such a grant, or a noncompetitive administrative supplement to such a grant, the Director of such national research institute or national center shall, consistent with the peer review process—

  * (A) review and make the final decision with respect to making the award; and

  * (B) take into consideration, as appropriate—

    * (i) the mission of the national research institute or national center and the scientific priorities identified in the strategic plan under section 282(m) of this title;

    * (ii) programs or projects funded by other agencies on similar research topics; and

    * (iii) advice by staff and the advisory council or board of such national research institute or national center.

#### (c) Coordination with other public and private entities; cooperation with other national research institutes; appointment of additional peer review groups
* In carrying out subsection (b), each Director of a national research institute—

  * (1) shall coordinate, as appropriate, the activities of the institute with similar programs of other public and private entities;

  * (2) shall cooperate with the Directors of the other national research institutes in the development and support of multidisciplinary research and research that involves more than one institute;

  * (3) may, in consultation with the advisory council for the Institute and with the approval of the Director of NIH—

    * (A) establish technical and scientific peer review groups in addition to those appointed under section 282(b)(16) of this title; and

    * (B) appoint the members of peer review groups established under subparagraph (A); and


  * (4) may publish, or arrange for the publication of, information with respect to the purpose of the Institute without regard to section 501 of title 44.


* The Federal Advisory Committee Act shall not apply to the duration of a peer review group appointed under paragraph (3).

### §284a. Advisory councils
#### (a) Establishment; acceptance of conditional gifts; functions
* (1) Except as provided in subsection (h), the Secretary shall appoint an advisory council for each national research institute which (A) shall advise, assist, consult with, and make recommendations to the Secretary and the Director of such institute on matters related to the activities carried out by and through the institute and the policies respecting such activities, and (B) shall carry out the special functions prescribed by part C.

* (2) Each advisory council for a national research institute may recommend to the Secretary acceptance, in accordance with section 238 of this title, of conditional gifts for study, investigation, or research respecting the diseases, disorders, or other aspect of human health with respect to which the institute was established, for the acquisition of grounds, or for the construction, equipping, or maintenance of facilities for the institute.

* (3) Each advisory council for a national research institute—

  * (A)(i) may on the basis of the materials provided under section 289a(b)(2) of this title respecting research conducted at the institute, make recommendations to the Director of the institute respecting such research,

  * (ii) may review applications for grants and cooperative agreements for research or training and for which advisory council approval is required under section 284(b)(2) of this title and recommend for approval applications for projects which show promise of making valuable contributions to human knowledge, and

  * (iii) may review any grant, contract, or cooperative agreement proposed to be made or entered into by the institute;

  * (B) may collect, by correspondence or by personal investigation, information as to studies which are being carried on in the United States or any other country as to the diseases, disorders, or other aspect of human health with respect to which the institute was established and with the approval of the Director of the institute make available such information through appropriate publications for the benefit of public and private health entities and health professions personnel and scientists and for the information of the general public; and

  * (C) may appoint subcommittees and convene workshops and conferences.

#### (b) Membership; compensation
* (1) Each advisory council shall consist of ex officio members and not more than eighteen members appointed by the Secretary. The ex officio members shall be nonvoting members.

* (2) The ex officio members of an advisory council shall consist of—

  * (A) the Secretary, the Director of NIH, the Director of the national research institute for which the council is established, the Under Secretary for Health of the Department of Veterans Affairs or the Chief Dental Director of the Department of Veterans Affairs, and the Assistant Secretary of Defense for Health Affairs (or the designees of such officers), and

  * (B) such additional officers or employees of the United States as the Secretary determines necessary for the advisory council to effectively carry out its functions.


* (3) The members of an advisory council who are not ex officio members shall be appointed as follows:

  * (A) Two-thirds of the members shall be appointed by the Secretary from among the leading representatives of the health and scientific disciplines (including not less than two individuals who are leaders in the fields of public health and the behavioral or social sciences) relevant to the activities of the national research institute for which the advisory council is established.

  * (B) One-third of the members shall be appointed by the Secretary from the general public and shall include leaders in fields of public policy, law, health policy, economics, and management.


* (4) Members of an advisory council who are officers or employees of the United States shall not receive any compensation for service on the advisory council. The other members of an advisory council shall receive, for each day (including traveltime) they are engaged in the performance of the functions of the advisory council, compensation at rates not to exceed the daily equivalent of the annual rate in effect for grade GS–18 of the General Schedule.

#### (c) Term of office; reappointment; vacancy
* The term of office of an appointed member of an advisory council is four years, except that any member appointed to fill a vacancy for an unexpired term shall be appointed for the remainder of such term and the Secretary shall make appointments to an advisory council in such a manner as to ensure that the terms of the members do not all expire in the same year. A member may serve after the expiration of the member's term for 180 days after the date of such expiration. A member who has been appointed for a term of four years may not be reappointed to an advisory council before two years from the date of expiration of such term of office. If a vacancy occurs in the advisory council among the appointed members, the Secretary shall make an appointment to fill the vacancy within 90 days from the date the vacancy occurs.

#### (d) Chairman; term of office
* The chairman of an advisory council shall be selected by the Secretary from among the appointed members, except that the Secretary may select the Director of the national research institute for which the advisory council is established to be the chairman of the advisory council. The term of office of the chairman shall be two years.

#### (e) Meetings
* The advisory council shall meet at the call of the chairman or upon the request of the Director of the national research institute for which it was established, but at least three times each fiscal year. The location of the meetings of each advisory council is subject to the approval of the Director of the national research institute for which the advisory council was established.

#### (f) Appointment of executive secretary; training and orientation for new members
* The Director of the national research institute for which an advisory council is established shall designate a member of the staff of the institute to serve as the executive secretary of the advisory council. The Director of such institute shall make available to the advisory council such staff, information, and other assistance as it may require to carry out its functions. The Director of such institute shall provide orientation and training for new members of the advisory council to provide them with such information and training as may be appropriate for their effective participation in the functions of the advisory council.

#### (g) Comments and recommendations for inclusion in biennial report; additional reports
* Each advisory council may prepare, for inclusion in the biennial report made under section 284b of this title, (1) comments respecting the activities of the advisory council in the fiscal years respecting which the report is prepared, (2) comments on the progress of the national research institute for which it was established in meeting its objectives, and (3) recommendations respecting the future directions and program and policy emphasis of the institute. Each advisory council may prepare such additional reports as it may determine appropriate.

#### (h) Advisory councils in existence; application of section to National Cancer Advisory Board and advisory council to National Heart, Lung, and Blood Institute
* (1) Except as provided in paragraph (2), this section does not terminate the membership of any advisory council for a national research institute which was in existence on November 20, 1985. After November 20, 1985—

  * (A) the Secretary shall make appointments to each such advisory council in such a manner as to bring about as soon as practicable the composition for such council prescribed by this section;

  * (B) each advisory council shall organize itself in accordance with this section and exercise the functions prescribed by this section; and

  * (C) the Director of each national research institute shall perform for such advisory council the functions prescribed by this section.


* (2)(A) The National Cancer Advisory Board shall be the advisory council for the National Cancer Institute. This section applies to the National Cancer Advisory Board, except that—

  * (i) appointments to such Board shall be made by the President;

  * (ii) the term of office of an appointed member shall be 6 years;

  * (iii) of the members appointed to the Board—

    * (I) not less than 5 members shall be individuals knowledgeable in environmental carcinogenesis (including carcinogenesis involving occupational and dietary factors); and

    * (II) not less than one member shall be an individual knowledgeable in pediatric oncology;


  * (iv) the chairman of the Board shall be selected by the President from the appointed members and shall serve as chairman for a term of two years;

  * (v) the ex officio members of the Board shall be nonvoting members and shall be the Secretary, the Director of the Office of Science and Technology Policy, the Director of NIH, the Under Secretary for Health of the Department of Veterans Affairs, the Director of the National Institute for Occupational Safety and Health, the Director of the National Institute of Environmental Health Sciences, the Secretary of Labor, the Commissioner of the Food and Drug Administration, the Administrator of the Environmental Protection Agency, the Chairman of the Consumer Product Safety Commission, the Assistant Secretary of Defense for Health Affairs, and the Director of the Office of Science of the Department of Energy (or the designees of such officers); and

  * (vi) the Board shall meet at least four times each fiscal year.


* (B) This section applies to the advisory council to the National Heart, Lung, and Blood Institute, except that the advisory council shall meet at least four times each fiscal year.

### §284c. Certain uses of funds
* (a)(1) Except as provided in paragraph (2), the sum of the amounts obligated in any fiscal year for administrative expenses of the National Institutes of Health may not exceed an amount which is 5.5 percent of the total amount appropriated for such fiscal year for the National Institutes of Health.

* (2) Paragraph (1) does not apply to the National Library of Medicine, the National Center for Nursing Research, the John E. Fogarty International Center for Advanced Study in the Health Sciences, the Warren G. Magnuson Clinical Center, and the Office of Medical Applications of Research.

* (3) For purposes of paragraph (1), the term "administrative expenses" means expenses incurred for the support of activities relevant to the award of grants, contracts, and cooperative agreements and expenses incurred for general administration of the scientific programs and activities of the National Institutes of Health.

* (b) For fiscal year 1989 and subsequent fiscal years, amounts made available to the National Institutes of Health shall be available for payment of nurses and allied health professionals in accordance with payment authorities, scheduling options, benefits, and other authorities provided under chapter 73 of title 38 for nurses of the Department of Veterans Affairs.

### §284d. Definitions
#### (a) Health service research
* For purposes of this subchapter, the term "health services research" means research endeavors that study the impact of the organization, financing and management of health services on the quality, cost, access to and outcomes of care. Such term does not include research on the efficacy of services to prevent, diagnose, or treat medical conditions.

#### (b) Clinical research
* As used in this subchapter, the term "clinical research" means patient oriented clinical research conducted with human subjects, or research on the causes and consequences of disease in human populations involving material of human origin (such as tissue specimens and cognitive phenomena) for which an investigator or colleague directly interacts with human subjects in an outpatient or inpatient setting to clarify a problem in human physiology, pathophysiology or disease, or epidemiologic or behavioral studies, outcomes research or health services research, or developing new technologies, therapeutic interventions, or clinical trials.

### §284e. Research on osteoporosis, Paget's disease, and related bone disorders
#### (a) Establishment
* The Directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, the National Institute of Dental Research, and the National Institute of Diabetes and Digestive and Kidney Diseases, shall expand and intensify the programs of such Institutes with respect to research and related activities concerning osteoporosis, Paget's disease, and related bone disorders.

#### (b) Coordination
* The Directors referred to in subsection (a) shall jointly coordinate the programs referred to in such subsection and consult with the Arthritis and Musculoskeletal Diseases Interagency Coordinating Committee and the Interagency Task Force on Aging Research.

#### (c) Information clearinghouse
* #### (1) In general
  * In order to assist in carrying out the purpose described in subsection (a), the Director of NIH shall provide for the establishment of an information clearinghouse on osteoporosis and related bone disorders to facilitate and enhance knowledge and understanding on the part of health professionals, patients, and the public through the effective dissemination of information.

* #### (2) Establishment through grant or contract
  * For the purpose of carrying out paragraph (1), the Director of NIH shall enter into a grant, cooperative agreement, or contract with a nonprofit private entity involved in activities regarding the prevention and control of osteoporosis and related bone disorders.

### §284f. Parkinson's disease
#### (a) In general
* The Director of NIH shall establish a program for the conduct and support of research and training with respect to Parkinson's disease (subject to the extent of amounts appropriated to carry out this section).

#### (b) Inter-institute coordination
* #### (1) In general
  * The Director of NIH shall provide for the coordination of the program established under subsection (a) among all of the national research institutes conducting Parkinson's disease research.

* #### (2) Conference
  * Coordination under paragraph (1) shall include the convening of a research planning conference not less frequently than once every 2 years. Each such conference shall prepare and submit to the Committee on Appropriations and the Committee on Labor and Human Resources of the Senate and the Committee on Appropriations and the Committee on Commerce of the House of Representatives a report concerning the conference.

#### (c) Morris K. Udall research centers
* #### (1) In general
  * The Director of NIH is authorized to award Core Center Grants to encourage the development of innovative multidisciplinary research and provide training concerning Parkinson's disease. The Director is authorized to award not more than 10 Core Center Grants and designate each center funded under such grants as a Morris K. Udall Center for Research on Parkinson's Disease.

* #### (2) Requirements
  * #### (A) In general
    * With respect to Parkinson's disease, each center assisted under this subsection shall—

      * (i) use the facilities of a single institution or a consortium of cooperating institutions, and meet such qualifications as may be prescribed by the Director of the NIH; and

      * (ii) conduct basic and clinical research.

  * #### (B) Discretionary requirements
    * With respect to Parkinson's disease, each center assisted under this subsection may—

      * (i) conduct training programs for scientists and health professionals;

      * (ii) conduct programs to provide information and continuing education to health professionals;

      * (iii) conduct programs for the dissemination of information to the public;

      * (iv) separately or in collaboration with other centers, establish a nationwide data system derived from patient populations with Parkinson's disease, and where possible, comparing relevant data involving general populations;

      * (v) separately or in collaboration with other centers, establish a Parkinson's Disease Information Clearinghouse to facilitate and enhance knowledge and understanding of Parkinson's disease; and

      * (vi) separately or in collaboration with other centers, establish a national education program that fosters a national focus on Parkinson's disease and the care of those with Parkinson's disease.

* #### (3) Stipends regarding training programs
  * A center may use funds provided under paragraph (1) to provide stipends for scientists and health professionals enrolled in training programs under paragraph (2)(B).

* #### (4) Duration of support
  * Support of a center under this subsection may be for a period not exceeding five years. Such period may be extended by the Director of NIH for one or more additional periods of not more than five years if the operations of such center have been reviewed by an appropriate technical and scientific peer review group established by the Director and if such group has recommended to the Director that such period should be extended.

#### (d) Morris K. Udall Awards for Excellence in Parkinson's Disease Research
* The Director of NIH is authorized to establish a grant program to support investigators with a proven record of excellence and innovation in Parkinson's disease research and who demonstrate potential for significant future breakthroughs in the understanding of the pathogensis, diagnosis, and treatment of Parkinson's disease. Grants under this subsection shall be available for a period of not to exceed 5 years.

### §284g. Expansion, intensification, and coordination of activities of National Institutes of Health with respect to research on autism spectrum disorder
#### (a) In general
* #### (1) Expansion of activities
  * The Director of NIH (in this section referred to as the "Director") shall, subject to the availability of appropriations, expand, intensify, and coordinate the activities of the National Institutes of Health with respect to research on autism spectrum disorder, including basic and clinical research in fields including pathology, developmental neurobiology, genetics, epigenetics, pharmacology, nutrition, immunology, neuroimmunology, neurobehavioral development, endocrinology, gastroenterology, toxicology, and interventions to maximize outcomes for individuals with autism spectrum disorder. Such research shall investigate the causes (including possible environmental causes), diagnosis or ruling out, early and ongoing detection, prevention, services across the lifespan, supports, intervention, and treatment of autism spectrum disorder, including dissemination and implementation of clinical care, supports, interventions, and treatments.

* #### (2) Consolidation
  * The Director may consolidate program activities under this section if such consolidation would improve program efficiencies and outcomes.

* #### (3) Administration of program; collaboration among agencies
  * The Director shall carry out this section acting through the Director of the National Institute of Mental Health and in collaboration with any other agencies that the Director determines appropriate.

#### (b) Centers of excellence
* #### (1) In general
  * The Director shall under subsection (a)(1) make awards of grants and contracts to public or nonprofit private entities to pay all or part of the cost of planning, establishing, improving, and providing basic operating support for centers of excellence regarding research on autism spectrum disorder.

* #### (2) Research
  * Each center under paragraph (1) shall conduct basic and clinical research into autism spectrum disorder. Such research should include investigations into the causes, diagnosis, early and ongoing detection, prevention, and treatment of autism spectrum disorder across the lifespan. The centers, as a group, shall conduct research including the fields of developmental neurobiology, genetics, genomics, psychopharmacology, developmental psychology, behavioral psychology, and clinical psychology.

* #### (3) Services for patients
  * #### (A) In general
    * A center under paragraph (1) may expend amounts provided under such paragraph to carry out a program to make individuals aware of opportunities to participate as subjects in research conducted by the centers.

  * #### (B) Referrals and costs
    * A program under subparagraph (A) may, in accordance with such criteria as the Director may establish, provide to the subjects described in such subparagraph, referrals for health and other services, and such patient care costs as are required for research.

  * #### (C) Availability and access
    * The extent to which a center can demonstrate availability and access to clinical services shall be considered by the Director in decisions about awarding grants to applicants which meet the scientific criteria for funding under this section.

  * #### (D) Reducing disparities
    * The Director may consider, as appropriate, the extent to which a center can demonstrate availability and access to clinical services for youth and adults from diverse racial, ethnic, geographic, or linguistic backgrounds in decisions about awarding grants to applicants which meet the scientific criteria for funding under this section.

* #### (4) Organization of centers
  * Each center under paragraph (1) shall use the facilities of a single institution, or be formed from a consortium of cooperating institutions, meeting such requirements as may be prescribed by the Director.

* #### (5) Number of centers; duration of support
  * #### (A) In general
    * The Director shall provide for the establishment of not less than five centers under paragraph (1).

  * #### (B) Duration
    * Support for a center established under paragraph (1) may be provided under this section for a period of not to exceed 5 years. Such period may be extended for one or more additional periods not exceeding 5 years if the operations of such center have been reviewed by an appropriate technical and scientific peer review group established by the Director and if such group has recommended to the Director that such period should be extended.

#### (c) Facilitation of research
* The Director shall under subsection (a)(1) provide for a program under which samples of tissues and genetic materials that are of use in research on autism spectrum disorder are donated, collected, preserved, and made available for such research. The program shall be carried out in accordance with accepted scientific and medical standards for the donation, collection, and preservation of such samples.

#### (d) Public input
* The Director shall under subsection (a)(1) provide for means through which the public can obtain information on the existing and planned programs and activities of the National Institutes of Health with respect to autism spectrum disorder and through which the Director can receive comments from the public regarding such programs and activities.

### §284h. Pediatric Research Initiative
#### (a) Establishment
* The Secretary shall establish within the Office of the Director of NIH a Pediatric Research Initiative (referred to in this section as the "Initiative") to conduct and support research that is directly related to diseases, disorders, and other conditions in children. The Initiative shall be headed by the Director of NIH.

#### (b) Purpose
* The purpose of the Initiative is to provide funds to enable the Director of NIH—

  * (1) to increase support for pediatric biomedical research within the National Institutes of Health to realize the expanding opportunities for advancement in scientific investigations and care for children;

  * (2) to enhance collaborative efforts among the Institutes to conduct and support multidisciplinary research in the areas that the Director deems most promising; and

  * (3) in coordination with the Food and Drug Administration, to increase the development of adequate pediatric clinical trials and pediatric use information to promote the safer and more effective use of prescription drugs in the pediatric population.

#### (c) Duties
* In carrying out subsection (b), the Director of NIH shall—

  * (1) consult with the Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the other national research institutes, in considering their requests for new or expanded pediatric research efforts, and consult with the Administrator of the Health Resources and Services Administration and other advisors as the Director determines to be appropriate;

  * (2) have broad discretion in the allocation of any Initiative assistance among the Institutes, among types of grants, and between basic and clinical research so long as the assistance is directly related to the illnesses and conditions of children; and

  * (3) be responsible for the oversight of any newly appropriated Initiative funds and annually report to Congress and the public on the extent of the total funds obligated to conduct or support pediatric research across the National Institutes of Health, including the specific support and research awards allocated through the Initiative.

#### (d) National Pediatric Research Network
* #### (1) Network
  * In carrying out the Initiative, the Director of NIH, in collaboration with the national research institutes and national centers that carry out activities involving pediatric research, shall support a National Pediatric Research Network in order to more effectively support pediatric research and optimize the use of Federal resources. Such National Pediatric Research Network may be comprised of, as appropriate—

    * (A) the pediatric research consortia receiving awards under paragraph (2); or

    * (B) other consortia, centers, or networks focused on pediatric research that are recognized by the Director of NIH and established pursuant to the authorities vested in the National Institutes of Health by other sections of this chapter.

* #### (2) Pediatric research consortia
  * #### (A) In general
    * The Director of NIH shall award funding, including through grants, contracts, or other mechanisms, to public or private nonprofit entities for providing support for pediatric research consortia, including with respect to—

      * (i) basic, clinical, behavioral, or translational research to meet unmet needs for pediatric research; and

      * (ii) training researchers in pediatric research techniques in order to address unmet pediatric research needs.

  * #### (B) Research
    * The Director of NIH shall, as appropriate, ensure that—

      * (i) each consortium receiving an award under subparagraph (A) conducts or supports at least one category of research described in subparagraph (A)(i) and collectively such consortia conduct or support such categories of research; and

      * (ii) one or more such consortia provide training described in subparagraph (A)(ii).

  * #### (C) Organization of consortium
    * Each consortium receiving an award under subparagraph (A) shall—

      * (i) be formed from a collaboration of cooperating institutions;

      * (ii) be coordinated by a lead institution or institutions;

      * (iii) agree to disseminate scientific findings, including from clinical trials, rapidly and efficiently, as appropriate, to—

        * (I) other consortia;

        * (II) the National Institutes of Health;

        * (III) the Food and Drug Administration;

        * (IV) and other relevant agencies; and


      * (iv) meet such requirements as may be prescribed by the Director of NIH.

  * #### (D) Supplement, not supplant
    * Any support received by a consortium under subparagraph (A) shall be used to supplement, and not supplant, other public or private support for activities authorized to be supported under this paragraph.

  * #### (E) Duration of support
    * Support of a consortium under subparagraph (A) shall be for a period of not to exceed 5 years. Such period may be extended at the discretion of the Director of NIH.

* #### (3) Coordination of consortia activities
  * The Director of NIH shall, as appropriate—

    * (A) provide for the coordination of activities (including the exchange of information and regular communication) among the consortia established pursuant to paragraph (2); and

    * (B) require the periodic preparation and submission to the Director of reports on the activities of each such consortium.

* #### (4) Assistance with registries
  * Each consortium receiving an award under paragraph (2)(A) may provide assistance, as appropriate, to the Centers for Disease Control and Prevention for activities related to patient registries and other surveillance systems upon request by the Director of the Centers for Disease Control and Prevention.

#### (e) Research on pediatric rare diseases or conditions
* In making awards under subsection (d)(2) for pediatric research consortia, the Director of NIH shall ensure that an appropriate number of such awards are awarded to such consortia that agree to—

  * (1) consider pediatric rare diseases or conditions, or those related to birth defects; and

  * (2) conduct or coordinate one or more multisite clinical trials of therapies for, or approaches to, the prevention, diagnosis, or treatment of one or more pediatric rare diseases or conditions.

#### (f) Transfer of funds
* The Director of NIH may transfer amounts appropriated under this section to any of the Institutes for a fiscal year to carry out the purposes of the Initiative under this section.

### §284i. Autoimmune diseases
#### (a) Expansion, intensification, and coordination of activities
* #### (1) In general
  * The Director of NIH shall expand, intensify, and coordinate research and other activities of the National Institutes of Health with respect to autoimmune diseases.

* #### (2) Allocations by Director of NIH
  * With respect to amounts appropriated to carry out this section for a fiscal year, the Director of NIH shall allocate the amounts among the national research institutes that are carrying out paragraph (1).

* #### (3) Definition
  * The term "autoimmune disease" includes, for purposes of this section such diseases or disorders with evidence of autoimmune pathogensis as the Secretary determines to be appropriate.

#### (b) Coordinating Committee
* #### (1) In general
  * The Secretary shall ensure that the Autoimmune Diseases Coordinating Committee (referred to in this section as the "Coordinating Committee") coordinates activities across the National Institutes and with other Federal health programs and activities relating to such diseases.

* #### (2) Composition
  * The Coordinating Committee shall be composed of the directors or their designees of each of the national research institutes involved in research with respect to autoimmune diseases and representatives of all other Federal departments and agencies whose programs involve health functions or responsibilities relevant to such diseases, including the Centers for Disease Control and Prevention and the Food and Drug Administration.

* #### (3) Chair
  * #### (A) In general
    * With respect to autoimmune diseases, the Chair of the Committee shall serve as the principal advisor to the Secretary, the Assistant Secretary for Health, and the Director of NIH, and shall provide advice to the Director of the Centers for Disease Control and Prevention, the Commissioner of Food and Drugs, and other relevant agencies.

  * #### (B) Director of NIH
    * The Chair of the Committee shall be directly responsible to the Director of NIH.

#### (c) Plan for NIH activities
* #### (1) In general
  * Not later than 1 year after October 17, 2000, the Coordinating Committee shall develop a plan for conducting and supporting research and education on autoimmune diseases through the national research institutes and shall periodically review and revise the plan. The plan shall—

    * (A) provide for a broad range of research and education activities relating to biomedical, psychosocial, and rehabilitative issues, including studies of the disproportionate impact of such diseases on women;

    * (B) identify priorities among the programs and activities of the National Institutes of Health regarding such diseases; and

    * (C) reflect input from a broad range of scientists, patients, and advocacy groups.

* #### (2) Certain elements of plan
  * The plan under paragraph (1) shall, with respect to autoimmune diseases, provide for the following as appropriate:

    * (A) Research to determine the reasons underlying the incidence and prevalence of the diseases.

    * (B) Basic research concerning the etiology and causes of the diseases.

    * (C) Epidemiological studies to address the frequency and natural history of the diseases, including any differences among the sexes and among racial and ethnic groups.

    * (D) The development of improved screening techniques.

    * (E) Clinical research for the development and evaluation of new treatments, including new biological agents.

    * (F) Information and education programs for health care professionals and the public.

* #### (3) Implementation of plan
  * The Director of NIH shall ensure that programs and activities of the National Institutes of Health regarding autoimmune diseases are implemented in accordance with the plan under paragraph (1).

### §284j. Muscular dystrophy research
#### (a) Coordination of activities
* The Director of NIH shall expand and increase coordination in the activities of the National Institutes of Health with respect to research on muscular dystrophies, including Duchenne muscular dystrophy.

#### (b) Administration of program; collaboration among agencies
* The Director of NIH shall carry out this section through the appropriate institutes, including the National Institute of Neurological Disorders and Stroke and in collaboration with any other agencies that the Director determines appropriate.

### §284k. Clinical research
#### (a) In general
* The Director of National Institutes of Health shall undertake activities to support and expand the involvement of the National Institutes of Health in clinical research.

#### (b) Requirements
* In carrying out subsection (a), the Director of National Institutes of Health shall—

  * (1) consider the recommendations of the Division of Research Grants Clinical Research Study Group and other recommendations for enhancing clinical research; and

  * (2) establish intramural and extramural clinical research fellowship programs directed specifically at medical and dental students and a continuing education clinical research training program at the National Institutes of Health.

#### (c) Support for the diverse needs of clinical research
* The Director of National Institutes of Health, in cooperation with the Directors of the Institutes, Centers, and Divisions of the National Institutes of Health, shall support and expand the resources available for the diverse needs of the clinical research community, including inpatient, outpatient, and critical care clinical research.

#### (d) Peer review
* The Director of National Institutes of Health shall establish peer review mechanisms to evaluate applications for the awards and fellowships provided for in subsection (b)(2) and section 284l of this title. Such review mechanisms shall include individuals who are exceptionally qualified to appraise the merits of potential clinical research training and research grant proposals.

### §284_l_. Enhancement awards
#### (a) Mentored Patient-Oriented Research Career Development Awards
* #### (1) Grants
  * #### (A) In general
    * The Director of the National Institutes of Health shall make grants (to be referred to as "Mentored Patient-Oriented Research Career Development Awards") to support individual careers in clinical research at general clinical research centers or at other institutions that have the infrastructure and resources deemed appropriate for conducting patient-oriented clinical research.

  * #### (B) Use
    * Grants under subparagraph (A) shall be used to support clinical investigators in the early phases of their independent careers by providing salary and such other support for a period of supervised study.

* #### (2) Applications
  * An application for a grant under this subsection shall be submitted by an individual scientist at such time as the Director may require.

#### (b) Mid-Career Investigator Awards in Patient-Oriented Research
* #### (1) Grants
  * #### (A) In general
    * The Director of the National Institutes of Health shall make grants (to be referred to as "Mid-Career Investigator Awards in Patient-Oriented Research") to support individual clinical research projects at general clinical research centers or at other institutions that have the infrastructure and resources deemed appropriate for conducting patient-oriented clinical research.

  * #### (B) Use
    * Grants under subparagraph (A) shall be used to provide support for mid-career level clinicians to allow such clinicians to devote time to clinical research and to act as mentors for beginning clinical investigators.

* #### (2) Applications
  * An application for a grant under this subsection shall be submitted by an individual scientist at such time as the Director requires.

#### (c) Graduate Training in Clinical Investigation Award
* #### (1) In general
  * The Director of the National Institutes of Health shall make grants (to be referred to as "Graduate Training in Clinical Investigation Awards") to support individuals pursuing master's or doctoral degrees in clinical investigation.

* #### (2) Applications
  * An application for a grant under this subsection shall be submitted by an individual scientist at such time as the Director may require.

* #### (3) Limitations
  * Grants under this subsection shall be for terms of 2 years or more and shall provide stipend, tuition, and institutional support for individual advanced degree programs in clinical investigation.

* #### (4) Definition
  * As used in this subsection, the term "advanced degree programs in clinical investigation" means programs that award a master's or Ph.D. degree in clinical investigation after 2 or more years of training in areas such as the following:

    * (A) Analytical methods, biostatistics, and study design.

    * (B) Principles of clinical pharmacology and pharmacokinetics.

    * (C) Clinical epidemiology.

    * (D) Computer data management and medical informatics.

    * (E) Ethical and regulatory issues.

    * (F) Biomedical writing.

#### (d) Clinical Research Curriculum Awards
* #### (1) In general
  * The Director of the National Institutes of Health shall make grants (to be referred to as "Clinical Research Curriculum Awards") to institutions for the development and support of programs of core curricula for training clinical investigators, including medical students. Such core curricula may include training in areas such as the following:

    * (A) Analytical methods, biostatistics, and study design.

    * (B) Principles of clinical pharmacology and pharmacokinetics.

    * (C) Clinical epidemiology.

    * (D) Computer data management and medical informatics.

    * (E) Ethical and regulatory issues.

    * (F) Biomedical writing.

* #### (2) Applications
  * An application for a grant under this subsection shall be submitted by an individual institution or a consortium of institutions at such time as the Director may require. An institution may submit only one such application.

* #### (3) Limitations
  * Grants under this subsection shall be for terms of up to 5 years and may be renewable.

### §284m. Program for pediatric studies of drugs
#### (a) List of priority issues in pediatric therapeutics
* #### (1) In general
  * Not later than one year after September 27, 2007, the Secretary, acting through the Director of the National Institutes of Health and in consultation with the Commissioner of Food and Drugs and experts in pediatric research, shall develop and publish a priority list of needs in pediatric therapeutics, including drugs, biological products, or indications that require study. The list shall be revised every three years.

* #### (2) Consideration of available information
  * In developing and prioritizing the list under paragraph (1), the Secretary—

    * (A) shall consider—

      * (i) therapeutic gaps in pediatrics that may include developmental pharmacology, pharmacogenetic determinants of drug response, metabolism of drugs and biologics in children, and pediatric clinical trials;

      * (ii) particular pediatric diseases, disorders or conditions where more complete knowledge and testing of therapeutics, including drugs and biologics, and identification of biomarkers for such diseases, disorders, or conditions, may be beneficial in pediatric populations; and

      * (iii) the adequacy of necessary infrastructure to conduct pediatric pharmacological research, including research networks and trained pediatric investigators; and


    * (B) may consider the availability of qualified countermeasures (as defined in section 247d–6a of this title), security countermeasures (as defined in section 247d–6b of this title), and qualified pandemic or epidemic products (as defined in section 247d–6d of this title) to address the needs of pediatric populations, in consultation with the Assistant Secretary for Preparedness and Response, consistent with the purposes of this section.

#### (b) Pediatric studies and research
* The Secretary, acting through the National Institutes of Health, shall award funds to entities that have the expertise to conduct pediatric clinical trials or other research (including qualified universities, hospitals, laboratories, contract research organizations, practice groups, federally funded programs such as pediatric pharmacology research units, other public or private institutions, or individuals) to enable the entities to conduct the drug studies or other research on the issues described in paragraphs (1) and (2)(A) of subsection (a). The Secretary may use contracts, grants, or other appropriate funding mechanisms to award funds under this subsection.

#### (c) Process for proposed pediatric study requests and labeling changes
* #### (1) Submission of proposed pediatric study request
  * The Director of the National Institutes of Health shall, as appropriate, submit proposed pediatric study requests for consideration by the Commissioner of Food and Drugs for pediatric studies of a specific pediatric indication identified under subsection (a). Such a proposed pediatric study request shall be made in a manner equivalent to a written request made under subsection (b) or (c) of section 505A of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355a], or section 262(m) of this title, including with respect to the information provided on the pediatric studies to be conducted pursuant to the request. The Director of the National Institutes of Health may submit a proposed pediatric study request for a drug for which—

    * (A)(i) there is an approved application under section 505(j) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(j)] or section 262(k) of this title; or

    * (ii) there is a submitted application that could be approved under the criteria of such section; and

    * (B) there remains no patent listed pursuant to section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(b)(1)], and every three-year and five-year period referred to in subsection (c)(3)(E)(ii), (c)(3)(E)(iii), (c)(3)(E)(iv), (j)(5)(F)(ii), (j)(5)(F)(iii), or (j)(5)(F)(iv) of section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], or applicable twelve-year period referred to in section 262(k)(7) of this title, and any seven-year period referred to in section 527 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 360cc] has ended for at least one form of the drug; and

    * (C) additional studies are needed to assess the safety and effectiveness of the use of the drug in the pediatric population.

* #### (2) Written request to holders of approved applications
  * The Commissioner of Food and Drugs, in consultation with the Director of the National Institutes of Health, may issue a written request based on the proposed pediatric study request for the indication or indications submitted pursuant to paragraph (1) (which shall include a timeframe for negotiations for an agreement) for pediatric studies concerning a drug identified under subsection (a) to all holders of an approved application for the drug. Such a written request shall be made in a manner equivalent to the manner in which a written request is made under subsection (b) or (c) of section 505A of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355a] or section 262(m) of this title, including with respect to information provided on the pediatric studies to be conducted pursuant to the request and using appropriate formulations for each age group for which the study is requested.

* #### (3) Requests for proposals
  * If the Commissioner of Food and Drugs does not receive a response to a written request issued under paragraph (2) not later than 30 days after the date on which a request was issued, the Secretary, acting through the Director of the National Institutes of Health and in consultation with the Commissioner of Food and Drugs, shall publish a request for proposals to conduct the pediatric studies described in the written request in accordance with subsection (b).

* #### (4) Disqualification
  * A holder that receives a first right of refusal shall not be entitled to respond to a request for proposals under paragraph (3).

* #### (5) Contracts, grants, or other funding mechanisms
  * A contract, grant, or other funding may be awarded under this section only if a proposal is submitted to the Secretary in such form and manner, and containing such agreements, assurances, and information as the Secretary determines to be necessary to carry out this section.

* #### (6) Reporting of studies
  * #### (A) In general
    * On completion of a pediatric study in accordance with an award under this section, a report concerning the study shall be submitted to the Director of the National Institutes of Health and the Commissioner of Food and Drugs. The report shall include all data generated in connection with the study, including a written request if issued.

  * #### (B) Availability of reports
    * #### (i) In general
      * Each report submitted under subparagraph (A) shall be considered to be in the public domain (subject to section 505A(d)(4) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355a(d)(4)]) and not later than 90 days after submission of such report, shall be—

        * (I) posted on the internet website of the National Institutes of Health in a manner that is accessible and consistent with all applicable Federal laws and regulations, including such laws and regulations for the protection of—

          * (aa) human research participants, including with respect to privacy, security, informed consent, and protected health information; and

          * (bb) proprietary interests, confidential commercial information, and intellectual property rights; and


        * (II) assigned a docket number by the Commissioner of Food and Drugs and made available for the submission of public comments.

    * #### (ii) Submission of comments
      * An interested person may submit written comments concerning such pediatric studies to the Commissioner of Food and Drugs, and the submitted comments shall become part of the docket file with respect to each of the drugs.

  * #### (C) Action by Commissioner
    * The Commissioner of Food and Drugs shall take action in a timely and appropriate manner in response to the reports submitted under subparagraph (A), and shall begin such action upon receipt of the report under subparagraph (A), in accordance with paragraph (7).

* #### (7) Requests for labeling change
  * Within the 180-day period after the date on which a report is submitted under paragraph (6)(A), the Commissioner of Food and Drugs shall—

    * (A) review the report and such other data as are available concerning the safe and effective use in the pediatric population of the drug studied;

    * (B) negotiate with the holders of approved applications for the drug studied for any labeling changes that the Commissioner of Food and Drugs determines to be appropriate and requests the holders to make; and

    * (C)(i) include in the public docket file a reference to the location of the report on the internet website of the National Institutes of Health and a copy of any requested labeling changes; and

    * (ii) publish through a posting on the Web site of the Food and Drug Administration a summary of the report and a copy of any requested labeling changes.

* #### (8) Dispute resolution
  * #### (A) Referral to Pediatric Advisory Committee
    * If, not later than the end of the 180-day period specified in paragraph (7), the holder of an approved application for the drug involved does not agree to any labeling change requested by the Commissioner of Food and Drugs under that paragraph, the Commissioner of Food and Drugs shall refer the request to the Pediatric Advisory Committee.

  * #### (B) Action by the Pediatric Advisory Committee
    * Not later than 90 days after receiving a referral under subparagraph (A), the Pediatric Advisory Committee shall—

      * (i) review the available information on the safe and effective use of the drug in the pediatric population, including study reports submitted under this section; and

      * (ii) make a recommendation to the Commissioner of Food and Drugs as to appropriate labeling changes, if any.

* #### (9) FDA determination
  * Not later than 30 days after receiving a recommendation from the Pediatric Advisory Committee under paragraph (8)(B)(ii) with respect to a drug, the Commissioner of Food and Drugs shall consider the recommendation and, if appropriate, make a request to the holders of approved applications for the drug to make any labeling change that the Commissioner of Food and Drugs determines to be appropriate.

* #### (10) Failure to agree
  * If a holder of an approved application for a drug, within 30 days after receiving a request to make a labeling change under paragraph (9), does not agree to make a requested labeling change, the Commissioner of Food and Drugs may deem the drug to be misbranded under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.].

* #### (11) No effect on authority
  * Nothing in this subsection limits the authority of the United States to bring an enforcement action under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.] when a drug lacks appropriate pediatric labeling. Neither course of action (the Pediatric Advisory Committee process or an enforcement action referred to in the preceding sentence) shall preclude, delay, or serve as the basis to stay the other course of action.

#### (d) Authorization of appropriations
* #### (1) In general
  * There are authorized to be appropriated to carry out this section, $25,000,000 for each of fiscal years 2018 through 2022.

* #### (2) Availability
  * Any amount appropriated under paragraph (1) shall remain available to carry out this section until expended.

### §284m–1. Pediatric Advisory Committee
#### (a) In general
* The Secretary of Health and Human Services shall, under section 217a of this title or other appropriate authority, convene and consult an advisory committee on pediatric therapeutics (including drugs and biological products) and medical devices (referred to in this section as the "advisory committee").

#### (b) Purpose
* #### (1) In general
  * The advisory committee shall advise and make recommendations to the Secretary, through the Commissioner of Food and Drugs, on matters relating to pediatric therapeutics (including drugs and biological products) and medical devices.

* #### (2) Matters included
  * The matters referred to in paragraph (1) include—

    * (A) pediatric research conducted under sections 262, 284m, and 290b of this title and sections 351, 352, 355, 355a, 355c, 360(k), 360e, and 360j(m) of title 21;

    * (B) identification of research priorities related to therapeutics (including drugs and biological products) and medical devices for pediatric populations and the need for additional diagnostics and treatments for specific pediatric diseases or conditions;

    * (C) the ethics, design, and analysis of clinical trials related to pediatric therapeutics (including drugs and biological products) and medical devices; and

    * (D) the development of countermeasures (as defined in section 360bbb–4(a) of title 21) for pediatric populations.

#### (c) Composition
* The advisory committee shall include representatives of pediatric health organizations, pediatric researchers, relevant patient and patient-family organizations, and other experts selected by the Secretary.

#### (d) Continuation of Operation of Committee
* Notwithstanding section 14 of the Federal Advisory Committee Act, the advisory committee shall continue to operate to carry out the advisory committee's responsibilities under sections 355a, 355c, and 360j(m) of title 21.

### §284n. Certain demonstration projects
#### (a) Bridging the sciences
* #### (1) In general
  * From amounts to be appropriated under section 282a(b) of this title, the Secretary of Health and Human Services, acting through the Director of NIH, (in this subsection referred to as the "Secretary") in consultation with the Director of the National Science Foundation, the Secretary of Energy, and other agency heads when necessary, may allocate funds for the national research institutes and national centers to make grants for the purpose of improving the public health through demonstration projects for biomedical research at the interface between the biological, behavioral, and social sciences and the physical, chemical, mathematical, and computational sciences.

* #### (2) Goals, priorities, and methods; interagency collaboration
  * The Secretary shall establish goals, priorities, and methods of evaluation for research under paragraph (1), and shall provide for interagency collaboration with respect to such research. In developing such goals, priorities, and methods, the Secretary shall ensure that—

    * (A) the research reflects the vision of innovation and higher risk with long-term payoffs; and

    * (B) the research includes a wide spectrum of projects, funded at various levels, with varying timeframes.

* #### (3) Peer review
  * A grant may be made under paragraph (1) only if the application for the grant has undergone technical and scientific peer review under section 289a of this title and has been reviewed by the advisory council under section 282(k) of this title or has been reviewed by an advisory council composed of representatives from appropriate scientific disciplines who can fully evaluate the applicant.

#### (b) High-risk, high-reward research
* #### (1) In general
  * From amounts to be appropriated under section 282a(b) of this title, the Secretary, acting through the Director of NIH, may allocate funds for the national research institutes and national centers to make awards of grants or contracts or to engage in other transactions for demonstration projects for high-impact, cutting-edge research that fosters scientific creativity and increases fundamental biological understanding leading to the prevention, diagnosis, and treatment of diseases and disorders. The head of a national research institute or national center may conduct or support such high-impact, cutting-edge research (with funds allocated under the preceding sentence or otherwise available for such purpose) if the institute or center gives notice to the Director of NIH beforehand and submits a report to the Director of NIH on an annual basis on the activities of the institute or center relating to such research.

* #### (2) Special consideration
  * In carrying out the program under paragraph (1), the Director of NIH shall give special consideration to coordinating activities with national research institutes whose budgets are substantial relative to a majority of the other institutes.

* #### (3) Administration of program
  * Activities relating to research described in paragraph (1) shall be designed by the Director of NIH or the head of a national research institute or national center, as applicable, to enable such research to be carried out with maximum flexibility and speed.

* #### (4) Public-private partnerships
  * In providing for research described in paragraph (1), the Director of NIH or the head of a national research institute or national center, as applicable, shall seek to facilitate partnerships between public and private entities and shall coordinate when appropriate with the Foundation for the National Institutes of Health.

* #### (5) Peer review
  * A grant for research described in paragraph (1) may be made only if the application for the grant has undergone technical and scientific peer review under section 289a of this title and has been reviewed by the advisory council under section 282(k) of this title.

#### (c) Report to Congress
* Not later than the end of fiscal year 2009, the Secretary, acting through the Director of NIH, shall conduct an evaluation of the activities under this section and submit a report to the Congress on the results of such evaluation.

#### (d) Definitions
* For purposes of this section, the terms "Director of NIH", "national research institute", and "national center" have the meanings given such terms in section 281 of this title.

### §284_o_. Activities of the National Institutes of Health with respect to research on paralysis
#### (a) Coordination
* The Director of the National Institutes of Health (referred to in this section and sections 280g–9 and 284p of this title as the "Director"), pursuant to the general authority of the Director, may develop mechanisms to coordinate the paralysis research and rehabilitation activities of the Institutes and Centers of the National Institutes of Health in order to further advance such activities and avoid duplication of activities.

#### (b) Christopher and Dana Reeve Paralysis Research Consortia
* #### (1) In general
  * The Director may make awards of grants to public or private entities to pay all or part of the cost of planning, establishing, improving, and providing basic operating support for consortia in paralysis research. The Director shall designate each consortium funded through such grants as a Christopher and Dana Reeve Paralysis Research Consortium.

* #### (2) Research
  * Each consortium under paragraph (1)—

    * (A) may conduct basic, translational, and clinical paralysis research;

    * (B) may focus on advancing treatments and developing therapies in paralysis research;

    * (C) may focus on one or more forms of paralysis that result from central nervous system trauma or stroke;

    * (D) may facilitate and enhance the dissemination of clinical and scientific findings; and

    * (E) may replicate the findings of consortia members or other researchers for scientific and translational purposes.

* #### (3) Coordination of consortia; reports
  * The Director may, as appropriate, provide for the coordination of information among consortia under paragraph (1) and ensure regular communication among members of the consortia, and may require the periodic preparation of reports on the activities of the consortia and the submission of the reports to the Director.

* #### (4) Organization of consortia
  * Each consortium under paragraph (1) may use the facilities of a single lead institution, or be formed from several cooperating institutions, meeting such requirements as may be prescribed by the Director.

#### (c) Public input
* The Director may provide for a mechanism to educate and disseminate information on the existing and planned programs and research activities of the National Institutes of Health with respect to paralysis and through which the Director can receive comments from the public regarding such programs and activities.

### §284p. Activities of the National Institutes of Health with respect to research with implications for enhancing daily function for persons with paralysis
#### (a) In general
* The Director, pursuant to the general authority of the Director, may make awards of grants to public or private entities to pay all or part of the costs of planning, establishing, improving, and providing basic operating support to multicenter networks of clinical sites that will collaborate to design clinical rehabilitation intervention protocols and measures of outcomes on one or more forms of paralysis that result from central nervous system trauma, disorders, or stroke, or any combination of such conditions.

#### (b) Research
* A multicenter network of clinical sites funded through this section may—

  * (1) focus on areas of key scientific concern, including—

    * (A) improving functional mobility;

    * (B) promoting behavioral adaptation to functional losses, especially to prevent secondary complications;

    * (C) assessing the efficacy and outcomes of medical rehabilitation therapies and practices and assisting technologies;

    * (D) developing improved assistive technology to improve function and independence; and

    * (E) understanding whole body system responses to physical impairments, disabilities, and societal and functional limitations; and


  * (2) replicate the findings of network members or other researchers for scientific and translation purposes.

#### (c) Coordination of clinical trials networks; reports
* The Director may, as appropriate, provide for the coordination of information among networks funded through this section and ensure regular communication among members of the networks, and may require the periodic preparation of reports on the activities of the networks and submission of reports to the Director.

### §284q. Pain research
#### (a) Research initiatives
* #### (1) In general
  * The Director of NIH is encouraged to continue and expand, through the Pain Consortium, an aggressive program of basic and clinical research on the causes of and potential treatments for pain.

* #### (2) Annual recommendations
  * Not less than annually, the Pain Consortium, in consultation with the Division of Program Coordination, Planning, and Strategic Initiatives, shall develop and submit to the Director of NIH recommendations on appropriate pain research initiatives that could be undertaken with funds reserved under section 282a(c)(1) of this title for the Common Fund or otherwise available for such initiatives.

* #### (3) Definition
  * In this subsection, the term "Pain Consortium" means the Pain Consortium of the National Institutes of Health or a similar trans-National Institutes of Health coordinating entity designated by the Secretary for purposes of this subsection.

#### (b) Interagency Pain Research Coordinating Committee
* #### (1) Establishment
  * The Secretary shall establish not later than 1 year after March 23, 2010, and as necessary maintain a committee, to be known as the Interagency Pain Research Coordinating Committee (in this section referred to as the "Committee"), to coordinate all efforts within the Department of Health and Human Services and other Federal agencies that relate to pain research.

* #### (2) Membership
  * #### (A) In general
    * The Committee shall be composed of the following voting members:

      * (i) Not more than 7 voting Federal representatives appoint by the Secretary from agencies that conduct pain care research and treatment.

      * (ii) 12 additional voting members appointed under subparagraph (B).

  * #### (B) Additional members
    * The Committee shall include additional voting members appointed by the Secretary as follows:

      * (i) 6 non-Federal members shall be appointed from among scientists, physicians, and other health professionals.

      * (ii) 6 members shall be appointed from members of the general public, who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions.

  * #### (C) Nonvoting members
    * The Committee shall include such nonvoting members as the Secretary determines to be appropriate.

* #### (3) Chairperson
  * The voting members of the Committee shall select a chairperson from among such members. The selection of a chairperson shall be subject to the approval of the Director of NIH.

* #### (4) Meetings
  * The Committee shall meet at the call of the chairperson of the Committee or upon the request of the Director of NIH, but in no case less often than once each year.

* #### (5) Duties
  * The Committee shall—

    * (A) develop a summary of advances in pain care research supported or conducted by the Federal agencies relevant to the diagnosis, prevention, treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration;

    * (B) identify critical gaps in basic and clinical research on—

      * (i) the symptoms and causes of pain, including the identification of relevant biomarkers and screening models and the epidemiology of acute and chronic pain;

      * (ii) the diagnosis, prevention, treatment, and management of acute and chronic pain, including with respect to non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; and

      * (iii) risk factors for, and early warning signs of, substance use disorders in populations with acute and chronic pain; and


    * (C) make recommendations to the Director of NIH—

      * (i) to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort;

      * (ii) on how best to disseminate information on pain care and epidemiological data related to acute and chronic pain; and

      * (iii) on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.

* #### (6) Report
  * The Secretary shall ensure that recommendations and actions taken by the Director with respect to the topics discussed at the meetings described in paragraph (4) are included in appropriate reports to Congress.

* #### (7) Review
  * The Secretary shall review the necessity of the Committee at least once every 2 years.

### §284q–1. NIH opioid research
#### (a) In general
* The Director of the National Institutes of Health (referred to in this section as the "NIH") may intensify and coordinate fundamental, translational, and clinical research of the NIH with respect to—

  * (1) the understanding of pain;

  * (2) the discovery and development of therapies for chronic pain; and

  * (3) the development of alternatives to opioids for effective pain treatments.

#### (b) Priority and direction
* The prioritization and direction of the Federally funded portfolio of pain research studies shall consider recommendations made by the Interagency Pain Research Coordinating Committee in concert with the Pain Management Best Practices Inter-Agency Task Force, and in accordance with the National Pain Strategy, the Federal Pain Research Strategy, and the NIH-Wide Strategic Plan for Fiscal Years 2016–2020, the latter of which calls for the relative burdens of individual diseases and medical disorders to be regarded as crucial considerations in balancing the priorities of the Federal research portfolio.

### §284r. Basic research
#### (1) Developing policies
* Not later than 2 years after December 13, 2016, the Director of the National Institutes of Health (referred to in this section as the "Director of the National Institutes of Health"), taking into consideration the recommendations developed under section 2039, shall develop policies for projects of basic research funded by National Institutes of Health to assess—

  * (A) relevant biological variables including sex, as appropriate; and

  * (B) how differences between male and female cells, tissues, or animals may be examined and analyzed.

#### (2) Revising policies
* The Director of the National Institutes of Health may update or revise the policies developed under paragraph (1) as appropriate.

#### (3) Consultation and outreach
* In developing, updating, or revising the policies under this section, the Director of the National Institutes of Health shall—

  * (A) consult with—

    * (i) the Office of Research on Women's Health;

    * (ii) the Office of Laboratory Animal Welfare; and

    * (iii) appropriate members of the scientific and academic communities; and


  * (B) conduct outreach to solicit feedback from members of the scientific and academic communities on the influence of sex as a variable in basic research, including feedback on when it is appropriate for projects of basic research involving cells, tissues, or animals to include both male and female cells, tissues, or animals.

#### (4) Additional requirements
* The Director of the National Institutes of Health shall—

  * (A) ensure that projects of basic research funded by the National Institutes of Health are conducted in accordance with the policies developed, updated, or revised under this section, as applicable; and

  * (B) encourage that the results of such research, when published or reported, be disaggregated as appropriate with respect to the analysis of any sex differences.

### §284s. Tick-borne diseases
#### (a) In general
* The Secretary of Health and Human Services (referred to in this section as "the Secretary") shall continue to conduct or support epidemiological, basic, translational, and clinical research related to vector-borne diseases, including tick-borne diseases.

#### (b) Reports
* The Secretary shall ensure that each triennial report under section 283 of this title (as amended by section 2032) includes information on actions undertaken by the National Institutes of Health to carry out subsection (a) with respect to tick-borne diseases.

#### (c) Tick-Borne Diseases Working Group
* #### (1) Establishment
  * The Secretary shall establish a working group, to be known as the Tick-Borne Disease Working Group (referred to in this section as the "Working Group"), comprised of representatives of appropriate Federal agencies and other non-Federal entities, to provide expertise and to review all efforts within the Department of Health and Human Services related to all tick-borne diseases, to help ensure interagency coordination and minimize overlap, and to examine research priorities.

* #### (2) Responsibilities
  * The working group shall—

    * (A) not later than 2 years after December 13, 2016, develop or update a summary of—

      * (i) ongoing tick-borne disease research, including research related to causes, prevention, treatment, surveillance, diagnosis, diagnostics, duration of illness, and intervention for individuals with tick-borne diseases;

      * (ii) advances made pursuant to such research;

      * (iii) Federal activities related to tick-borne diseases, including—

        * (I) epidemiological activities related to tick-borne diseases; and

        * (II) basic, clinical, and translational tick-borne disease research related to the pathogenesis, prevention, diagnosis, and treatment of tick-borne diseases;


      * (iv) gaps in tick-borne disease research described in clause (iii)(II);

      * (v) the Working Group's meetings required under paragraph (4); and

      * (vi) the comments received by the Working Group;


    * (B) make recommendations to the Secretary regarding any appropriate changes or improvements to such activities and research; and

    * (C) solicit input from States, localities, and nongovernmental entities, including organizations representing patients, health care providers, researchers, and industry regarding scientific advances, research questions, surveillance activities, and emerging strains in species of pathogenic organisms.

* #### (3) Membership
  * The members of the working group shall represent a diversity of scientific disciplines and views and shall be composed of the following members:

  * #### (A) Federal members
    * Seven Federal members, consisting of one or more representatives of each of the following:

      * (i) The Office of the Assistant Secretary for Health.

      * (ii) The Food and Drug Administration.

      * (iii) The Centers for Disease Control and Prevention.

      * (iv) The National Institutes of Health.

      * (v) Such other agencies and offices of the Department of Health and Human Services as the Secretary determines appropriate.

  * #### (B) Non–Federal public members
    * Seven non–Federal public members, consisting of representatives of the following categories:

      * (i) Physicians and other medical providers with experience in diagnosing and treating tick-borne diseases.

      * (ii) Scientists or researchers with expertise.

      * (iii) Patients and their family members.

      * (iv) Nonprofit organizations that advocate for patients with respect to tick-borne diseases.

      * (v) Other individuals whose expertise is determined by the Secretary to be beneficial to the functioning of the Working Group.

* #### (4) Meetings
  * The Working Group shall meet not less than twice each year.

* #### (5) Reporting
  * Not later than 2 years after December 13, 2016, and every 2 years thereafter until termination of the Working Group pursuant to paragraph (7), the Working Group shall—

    * (A) submit a report on its activities under paragraph (2)(A) and any recommendations under paragraph (2)(B) to the Secretary, the Committee on Energy and Commerce of the House of Representatives, and the Committee on Health, Education, Labor, and Pensions of the Senate; and

    * (B) make such report publicly available on the Internet website of the Department of Health and Human Services.

* #### (6) Applicability of FACA
  * The Working Group shall be treated as an advisory committee subject to the Federal Advisory Committee Act (5 U.S.C. App.).

* #### (7) Sunset
  * The Working Group under this section shall terminate 6 years after December 13, 2016.